We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+4.73%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.11B
AUM Growth
+$59.7M
Cap. Flow
+$37M
Cap. Flow %
3.34%
Top 10 Hldgs %
63.03%
Holding
52
New
19
Increased
6
Reduced
15
Closed
2
Avg Time Held Equity + Options
2.2 quarters
Top 10 Avg Time Held Equity + Options
5 quarters
Top 20 Avg Time Held Equity + Options
3.3 quarters
Avg Time Held Equity only
2.4 quarters
Top 10 Avg Time Held Equity only
5.2 quarters
Top 20 Avg Time Held Equity only
3.2 quarters

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$57.2M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$26.2M
3
AKCA
Akcea Therapeutics Inc
AKCA
+$22.8M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$20.7M
5
RUBY
Rubius Therapeutics, Inc
RUBY
+$13.5M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$55.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.9M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$20.9M
4
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$17.7M
5
WVE icon
Wave Life Sciences
WVE
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.05%
2 Miscellaneous 12.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KYNB icon
1
Kyntra Bio
KYNB
$23.8M
$123M 11.04%
80,690
– –
2014 Q4
15 quarters
ASMB icon
2
Assembly Biosciences
ASMB
$416M
$109M 9.85%
245,264
– –
2014 Q4
15 quarters
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$595M
$94.9M 8.55%
6,139,099
-1,323,488
-18% -$20.9M
2015 Q4
11 quarters
ASND icon
4
Ascendis Pharma A/S
ASND
$14.9B
$77M 6.94%
1,087,257
-376,810
-26% -$25.9M
2016 Q3
8 quarters
KURA icon
5
Kura Oncology
KURA
$861M
$68.3M 6.15%
3,902,975
-1,700
-0% -$32.6K
2015 Q4
11 quarters
SRRK icon
6
Scholar Rock
SRRK
$4.83B
$61M 5.49%
2,367,378
-303,783
-11% -$5.58M
2018 Q2
1 quarter
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$58M 5.23%
3,802,327
+841,180
+28% +$12.2M
2017 Q1
6 quarters
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$45.7M 4.11%
+837,048
New +$57.2M
2018 Q3
0 quarters
MGNX icon
9
MacroGenics
MGNX
$203M
$31.8M 2.86%
1,481,086
+30,480
+2% +$650K
2017 Q4
3 quarters
RCUS icon
10
Arcus Biosciences
RCUS
$2.89B
$31.2M 2.81%
2,236,387
– –
2018 Q1
2 quarters
KZR icon
11
DELISTED
Kezar Life Sciences
KZR
$27.6M 2.48%
128,820
+1,600
+1% +$279K
2018 Q2
1 quarter
AKCA
12
DELISTED
Akcea Therapeutics Inc
AKCA
$26.4M 2.38%
+755,120
New +$22.8M
2018 Q3
0 quarters
RARE icon
13
CALL
Ultragenyx Pharmaceutical
RARE
$1.47B
$24.8M 2.24%
+325,000
New +$26.4M
2018 Q3
0 quarters
GILD icon
14
CALL
Gilead Sciences
GILD
$188B
$22.6M 2.04%
292,600
– –
2018 Q2
1 quarter
CRSP icon
15
CRISPR Therapeutics
CRSP
$4.83B
$22.2M 2%
+500,000
New +$26.2M
2018 Q3
0 quarters
KYNB icon
16
CALL
Kyntra Bio
KYNB
$23.8M
$21.3M 1.92%
14,000
– –
2017 Q4
3 quarters
NKTR icon
17
CALL
Nektar Therapeutics
NKTR
$1.27B
$19.8M 1.78%
+21,667
New +$18.5M
2018 Q3
0 quarters
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$1.47B
$19.4M 1.75%
+254,000
New +$20.7M
2018 Q3
0 quarters
DNTH icon
19
Dianthus Therapeutics
DNTH
$4.24B
$18.5M 1.66%
96,131
– –
2018 Q2
1 quarter
ASND icon
20
CALL
Ascendis Pharma A/S
ASND
$14.9B
$18.2M 1.64%
257,000
-190,000
-43% -$13.1M
2018 Q2
1 quarter
CELG
21
CALL
DELISTED
Celgene Corp
CELG
$17.9M 1.61%
200,000
-385,000
-66% -$34M
2017 Q4
3 quarters
UBX icon
22
DELISTED
Unity Biotechnology
UBX
$15.8M 1.42%
96,711
-71,353
-42% -$11.7M
2018 Q2
1 quarter
SURF
23
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$14.9M 1.34%
1,363,479
+472,671
+53% +$5.54M
2018 Q2
1 quarter
RUBY
24
DELISTED
Rubius Therapeutics, Inc
RUBY
$14.2M 1.28%
+592,128
New +$13.5M
2018 Q3
0 quarters
EIGR
25
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$12.5M 1.12%
34,650
– –
2018 Q2
1 quarter
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2018 Portfolio in Review

As of Q3 2018, EcoR1 Capital held 52 positions worth $1.11B, up 5.7% from $1.05B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

EcoR1 Capital deployed $37M of net new capital in Q3 2018, opening 19 new positions and adding to 6 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 837,048 shares worth $45.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.9M trimmed.

  • EcoR1 Capital's largest Q3 2018 buy was Spark Therapeutics, Inc. Common Stock: 837,048 shares worth $45.7M.
  • EcoR1 Capital added most to Dicerna Pharmaceuticals, Inc. in Q3 2018, an estimated $12.2M increase.
  • EcoR1 Capital's biggest Q3 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.9M.
  • EcoR1 Capital fully exited Madrigal Pharmaceuticals in Q3 2018, selling an estimated $55.8M.
  • EcoR1 Capital's ten largest holdings make up 63% of its $1.11B portfolio in Q3 2018.
  • EcoR1 Capital opened 19 new positions and closed 2 in Q3 2018.
  • EcoR1 Capital's portfolio value rose 5.7% quarter-over-quarter to $1.11B.

Based on EcoR1 Capital's 13F filing for Q3 2018, filed 14 Nov 2018.